跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ROR1 Bispecific
首页
药物
ROR1 Bispecific
ROR1 Bispecific
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTI-ROR1/ANTI-CD3 BISPECIFIC BINDING MOLECULES
EP 3972999 A1
申请人: VELOSBIO INC
优先权: 2019
CN
EP
US
WO
5 件公开
ANTI-ROR1 ANTIBODIES AND RELATED BISPECIFIC BINDING PROTEINS
EP 4200336 A4
申请人: EPIMAB BIOTHERAPEUTICS HK LTD
优先权: 2020
CN
EP
US
WO
4 件公开
ANTI-ROR1 ANTIBODY, BISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF
US 20260015418 A1
申请人: ABL BIO INC
优先权: 2022
CN
EP
US
WO
4 件公开
BISPECIFIC ANTIBODY TARGETING HUMAN ROR1 AND CD3
EP 4782541 A1
申请人: NANJING PROBIO BIOTECH CO LTD
优先权: 2023
CN
EP
WO
3 件公开
BISPECIFIC ANTIBODIES TO ROR1 AND CD3
EP 3985026 A1
申请人: UCL BUSINESS LTD
优先权: 2017
EP
US
2 件公开
ANTI-ROR1/ANTI-4-1BB ANTIBODIES AND USES THEREOF
WO 2025051220 A9
申请人: TJ BIOPHARMA SHANGHAI CO LTD
优先权: 2023
CN
WO
2 件公开
Bispecific antibodies against CD3e and ROR1
EP 2789630 A1
申请人: ENGMAB AG
优先权: 2013
EP
Bispecific antibodies against CD3EPSILON and ROR1
US 11952421 B2
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2014
US
ANTI-ROR1 ANTIBODIES, ROR1 * CD3 BISPECIFIC ANTIBODIES, AND METHODS OF USING THE SAME
CN 108495864 A
申请人: JANSSEN BIOTECH INC
优先权: 2016
CN
Oncolytic viruses expressing anti-ROR1/anti-CD3 bispecific antibodies
CN 117460833 A
申请人: SORRENTO PHARMA INC
优先权: 2021
CN
第 1 / 2 页
上一页
下一页
药物
反馈